Skip to main content
Premium Trial:

Request an Annual Quote

Brenner Accolades Misattributed


Brenner Accolades Misattributed

Return to Sender

In “The Missing Lynx” (April 2001), Aaron Sender, in extolling “the brains behind Lynx’s patented inventions” describes Sydney Brenner as “known best for discovering (italics mine) mRNA and its triplet code of translation, as well as for introducing C. elegans as a model organism.” The latter attribute is correct, the first is not.

Elliot Volkin and Larry Astrachan, in the Biology Division at Oak Ridge National Laboratory, were the first to discover mRNA which they termed DNA-like RNA. It had the same base composition as the DNA of the bacteriophage infecting E. coli and turned over rapidly. Sydney Brenner coined the term mRNA for DNA-like RNA which had the properties of the unstable intermediate X postulated by François Jacob and Jacques Monod in their model of expression of the lactose operon. DNA-like RNA became mRNA! The triplet code for translation was implicated by several biologists and George Gamow, known best for his contributions to nuclear physics and cosmology! Experimental proof of the triplet codes for translation came from the studies of Marshall Nirenberg and Har Gobind Khorana, for which they were awarded the Nobel Prize in Biology/Medicine in 1968. The Nobel citation reads in part: “for their interpretation of the genetic code and its function in protein synthesis.”

Salil K. Niyogi, Senior Staff Scientist Emeritus, Oak Ridge National Laboratory

Be a Messenger

Unless requested otherwise, any correspondence to Genome Technology may be published. Letters may be edited for length and clarity. Send mail to [email protected] or mail to Editor, Genome Technology, PO Box 998, Peck Slip Station, New York, NY 10272-0998.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.